Clene Stock (NASDAQ:CLNN)
Previous Close
$6.20
52W Range
$3.82 - $12.00
50D Avg
$5.51
200D Avg
$6.88
Market Cap
$45.15M
Avg Vol (3M)
$137.47K
Beta
0.47
Div Yield
-
CLNN Company Profile
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
CLNN Performance
Peer Comparison
Ticker | Company |
---|---|
NGM | NGM Biopharmaceuticals, Inc. |
CYT | Cyteir Therapeutics, Inc. |
NUVB | Nuvation Bio Inc. |
NXTC | NextCure, Inc. |
IKNA | Ikena Oncology, Inc. |
FHTX | Foghorn Therapeutics Inc. |
MLYS | Mineralys Therapeutics, Inc. |
IPSC | Century Therapeutics, Inc. |
SNSE | Sensei Biotherapeutics, Inc. |
CSBR | Champions Oncology, Inc. |
GRPH | LENZ Therapeutics, Inc. |
MNOV | MediciNova, Inc. |
HOWL | Werewolf Therapeutics, Inc. |
NKTX | Nkarta, Inc. |
MOLN | Molecular Partners AG |
KZR | Kezar Life Sciences, Inc. |
MACK | Merrimack Pharmaceuticals, Inc. |
IMNM | Immunome, Inc. |
ELYM | Eliem Therapeutics, Inc. |